In the US IPO market’s busiest week since 2004, 19 IPOs raised nearly $10 billion, led by Chinese ride-hailing giant DiDi Global (DIDI). The second largest IPO of the year, DiDi (DIDI) upsized and priced at the high end to raise $4.4 billion at a...read more
Aerovate Therapeutics, which is developing an inhaled formulation of imatinib for pulmonary arterial hypertension (PAH), raised $122 million by offering 8.7 million shares at $14, within the range of $13 to $15. The company originally planned to raise $100 ...read more
17 IPOs are slated to raise $9.1 billion in the week ahead, led by long-awaited Chinese ride-hailing giant DiDi Global (DIDI).
DiDi (DIDI) plans to raise $3.9 billion at a $67.5 billion market cap. DiDi is China’s dominant ride-hailing app, with 15 ...read more
Aerovate Therapeutics, which is developing a dry powder drug formulation for pulmonary arterial hypertension, announced terms for its IPO on Thursday.
The Boston, MA-based company plans to raise $100 million by offering 7.2 million shares at a price range of ...read more
US IPO Weekly Recap: DiDi leads a 19 IPO week, the busiest since 2004
In the US IPO market’s busiest week since 2004, 19 IPOs raised nearly $10 billion, led by Chinese ride-hailing giant DiDi Global (DIDI). The second largest IPO of the year, DiDi (DIDI) upsized and priced at the high end to raise $4.4 billion at a...read more
PAH drug developer Aerovate Therapeutics prices upsized IPO at $14 midpoint
Aerovate Therapeutics, which is developing an inhaled formulation of imatinib for pulmonary arterial hypertension (PAH), raised $122 million by offering 8.7 million shares at $14, within the range of $13 to $15. The company originally planned to raise $100 ...read more
US IPO Week Ahead: DiDi makes its billion-dollar debut in a 17 IPO week
17 IPOs are slated to raise $9.1 billion in the week ahead, led by long-awaited Chinese ride-hailing giant DiDi Global (DIDI). DiDi (DIDI) plans to raise $3.9 billion at a $67.5 billion market cap. DiDi is China’s dominant ride-hailing app, with 15 ...read more
Drug formulation developer Aerovate Therapeutics sets terms for $100 million IPO
Aerovate Therapeutics, which is developing a dry powder drug formulation for pulmonary arterial hypertension, announced terms for its IPO on Thursday. The Boston, MA-based company plans to raise $100 million by offering 7.2 million shares at a price range of ...read more